Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with the Taiwan-based AbGenomics Corporation.

AbGenomics Corporation intends to use the PER.C6® cell line for its research, development and early clinical studies of monoclonal antibodies.

"The unique characteristics of the PER.C6® technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6® highly imperative,” said Shih-Yao Lin, PhD, AbGenomics Corporation’s President.

Under the terms of this agreement, AbGenomics Corporation will make license payments and annual maintenance fees in exchange for certain right. Further financial details were not disclosed.

About AbGenomics Corporation
AbGenomics Corporation is a biotechnology company focused on the discovery and development of breakthrough medicines to treat serious life threatening and debilitating diseased, including cancer, inflammations, autoimmune, infectious and metabolic diseases. The Company’s business strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners. For more information, please visit www.abgenomics.com

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.